PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
March 15, 2024Leukemia42 citationsOpen Access

CD22 CAR T cells demonstrate high response rates and safety in pediatric and adult B-ALL: Phase 1b results

View Full Paper
LSLiora M. SchultzNJNikeshan JeyakumarAKAnne Marijn Kramer

Key Points

Key points are not available for this paper at this time.

Abstract

Chimeric antigen receptor (CAR) T cells targeting CD22 (CD22-CAR) provide a therapeutic option for patients with CD22

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Schultz et al. (2024) studied this question.

synapsesocial.com/papers/68e73cb8b6db6435876b6061https://doi.org/10.1038/s41375-024-02220-y
Ask AI
Helpful
Bookmark
Share
View Full Paper

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Anti-CD22–chimeric antigen receptors targeting B-cell precursor acute lymphoblastic leukemia2012 · 586 citations
  2. 2Retention of CD19 intron 2 contributes to CART-19 resistance in leukemias with subclonal frameshift mutations in CD192019 · 119 citations
  3. 3Sequential CD19 and CD22 chimeric antigen receptor T-cell therapy for childhood refractory or relapsed B-cell acute lymphocytic leukaemia: a single-arm, phase 2 study2023 · 71 citations
  4. 4CD22-directed CAR T-cell therapy induces complete remissions in CD19-directed CAR–refractory large B-cell lymphoma2020 · 80 citations
  5. 5Coadministration of CD19- and CD22-Directed Chimeric Antigen Receptor T-Cell Therapy in Childhood B-Cell Acute Lymphoblastic Leukemia: A Single-Arm, Multicenter, Phase II Trial2022 · 103 citations